Table 6.
ID | Initiation Date | Phase | Nation | N | Disease | Treatment | Primary Outcome |
---|---|---|---|---|---|---|---|
NCT04163419 | 4, 2020 | 2 | USA | 46 | Schwannomatosis | Tanezumab | Change in pain level |
NCT04085159 | 9, 2019 | 1/2 | China | 100 | Neurofibromatosis Schwannomatosis | Antigen-specific T cells CART/CTL and DCvac | Percentage of adverse effects |